KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ:KALV
Want to see KALV full AI Analyst Report?
KALV Stock Chart & Stats
$20.48
-$0.39(-4.51%)
At close: 4:00 PM EST
$20.48
-$0.39(-4.51%)
Day’s Range― - ―
52-Week Range$9.83 - $26.98
Previous CloseN/A
Volume49.40K
Average Volume (3M)5.70M
Market Cap
$1.43B
Enterprise Value$1.49B
Total Cash (Recent Filing)$300.21M
Total Debt (Recent Filing)$284.21M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.28
Shares Outstanding53,240,887
10 Day Avg. Volume3,370,778
30 Day Avg. Volume5,704,997
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)-303.23
Price to Sales (P/S)11.17
P/FCF Ratio-9.87
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue12.82
Enterprise Value/Gross Profit16.36
Enterprise Value/Ebitda-8.02
Forecast
1Y Price Target
$29.17Price Target Upside42.42% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$207.69M
Bulls Say, Bears Say
Bulls Say
Acquisition Provides Clear Exit And Lowers Execution RiskThe all-cash acquisition agreement to be completed in 3Q26 removes KalVista’s need to independently raise financing and cuts standalone execution risk. This structural change improves near-term outcome visibility, transfers commercialization responsibility to Chiesi, and accelerates global access to EKTERLY.
Commercial Proof-of-concept: EKTERLY Early UptakeMaterial 2025 sales for EKTERLY demonstrate the company’s lead oral on-demand therapy can generate real-world revenues and market adoption. This durable commercial signal validates product-market fit and supports potential scaling under an acquirer with broader U.S. commercial capabilities.
Focused Pipeline Targeting Protease-driven HAEA clear scientific focus on small-molecule protease inhibitors for HAE gives KalVista differentiated product candidates (on-demand and prophylactic). This focused pipeline provides strategic optionality, concentrated R&D expertise, and a defensible niche against broader biologic-first competitors.
Bears Say
Significant Cash Burn And Large Operating LossesSustained, large operating and free cash flow deficits indicate high ongoing capital requirements. Absent the acquisition, continued cash burn would force frequent external financing or spending cuts, creating dilution and execution risk for late-stage development and commercialization over the coming months.
Weakened Balance Sheet And Elevated LeverageMaterial increase in debt and negative equity constrain financial flexibility and heighten refinancing risk. A leveraged balance sheet limits freedom to invest in pipeline expansion or commercial rollouts without relying on partners or M&A, complicating standalone sustainability until deal close.
History Of Limited Recurring Product Revenue; Financing-dependenceAs a clinical-stage company, KalVista has not generated consistent recurring revenues and has relied on equity and partnership funding. This structural revenue dependence raises long-term risk that commercial scale and steady cash flow will be hard to sustain without meaningful product diversification or integration into a larger commercial platform.
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals, Inc.’s price range in the past 12 months?
KalVista Pharmaceuticals, Inc. lowest stock price was $9.83 and its highest was $26.98 in the past 12 months.
What is KalVista Pharmaceuticals, Inc.’s market cap?
KalVista Pharmaceuticals, Inc.’s market cap is $1.43B.
When is KalVista Pharmaceuticals, Inc.’s upcoming earnings report date?
KalVista Pharmaceuticals, Inc.’s upcoming earnings report date is Sep 03, 2026 which is in 91 days.
How were KalVista Pharmaceuticals, Inc.’s earnings last quarter?
KalVista Pharmaceuticals, Inc. released its earnings results on Mar 17, 2026. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.672 by -$0.248.
Is KalVista Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts KalVista Pharmaceuticals, Inc.’s price is currently Undervalued.
Does KalVista Pharmaceuticals, Inc. pay dividends?
KalVista Pharmaceuticals, Inc. does not currently pay dividends.
What is KalVista Pharmaceuticals, Inc.’s EPS estimate?
KalVista Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KalVista Pharmaceuticals, Inc. have?
KalVista Pharmaceuticals, Inc. has 53,240,887 shares outstanding.
What happened to KalVista Pharmaceuticals, Inc.’s price movement after its last earnings report?
KalVista Pharmaceuticals, Inc. reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.672. Following the earnings report the stock price went down -1.546%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in KALV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KalVista Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.17 (42.42% Upside)
$29.17 (42.42% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 152.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 10.6%
Last 30 Days ▼ 10.6%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.87%
12-Months-Change
Fundamentals
Return on Equity
-1057.44%
Trailing 12-Months
Asset Growth
52.63%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Stock 12 Month Forecast
Average Price Target
$29.17
▲(42.42% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
11.69% Insiders
14.26% Mutual Funds
21.08% Other Institutional Investors
41.06% Public Companies and
Individual Investors